Niagen Bioscience, Inc. (NAGE) - 10-Q Summary
Business Context and Reporting Period
Company: Niagen Bioscience, Inc.
Reporting Period: Quarter and six months ended June 30, 2026
Business Overview: A global bioscience company focused on NAD+ precursors, primarily commercializing the ingredient Niagen® in consumer products (Tru Niagen®), ingredient supply, and pharmaceutical development. The company divested its Analytical Reference Standards and Services segment in February 2026.
Key Financial Metrics
| Metric (in thousands) | 3 Months Ended June 30, 2026 |
6 Months Ended June 30, 2026 |
|---|---|---|
| Net Sales | $29,785 | $61,259 |
| Gross Profit | $19,314 | $39,290 |
| Gross Margin | 64.8% | 64.1% |
| Operating Income | $700 | $2,276 |
| Net Income | $963 | $7,281 |
| Diluted EPS | $0.01 | $0.09 |
| Cash & Equivalents | $66,740 (as of June 30, 2026) | |
| Operating Cash Flow (6mo) | $1,578 |
Material Changes vs. Prior Period
- Revenue Decline: Net sales decreased 4% ($1.3M) for the quarter and 1% ($0.3M) for the six months compared to 2025. This was driven by a 29% drop in Ingredients segment sales and the absence of the divested Analytical Reference Standards segment, partially offset by a 6% increase in Consumer Products sales.
- Profitability Pressure: Operating income fell 78% ($2.5M) for the quarter and 71% ($5.7M) for the six months year-over-year. This decline is primarily due to increased Sales and Marketing expenses (up 23% for the quarter) and the loss of the high-margin Analytical Reference Standards segment.
- Segment Performance:
- Consumer Products: Sales grew 6% (QoQ) and 5% (6mo) driven by e-commerce expansion, though marketing spend increased significantly.
- Ingredients: Sales declined 29% (QoQ) and 12% (6mo) due to softer downstream demand and reduced pharmaceutical-grade sales.
- Divestiture Impact: The company recognized a $4.8 million gain on the sale of the Analytical Reference Standards segment in Q1 2026, which boosted net income for the six-month period but is not recurring.
Guidance, Outlook, and Risks
- Strategic Focus: Management is focusing on core Niagen®-based consumer products and ingredient supply following the divestiture. A new telehealth platform (Niagen Plus) was launched in May 2026 to expand direct-to-patient access.
- Pharmaceutical Development: The company introduced NB4168, a therapeutic candidate for Ataxia-Telangiectasia, which received Rare Pediatric Disease (RPD) and Orphan Medicinal Product Designation (OMPD) in July 2026.
- Liquidity: The company holds $66.7 million in cash and has an At-The-Market (ATM) facility to raise up to $50 million. Management believes current resources are sufficient for the next 12 months.
- Key Risks:
- Legal Proceedings: An ongoing appeal regarding a $9.2 million judgment (plus interest, totaling approx. $10.4 million) against Elysium Health, Inc. remains unresolved. No accrual has been recorded as the outcome is uncertain.
- Regulatory: The company is litigating against the FDA regarding the regulatory status of NMN, a competitor ingredient.
- Supplier Concentration: Reliance on a single supplier (W.R. Grace) for the key raw material NRC.
- Customer Concentration: Approximately 37% of trade receivables are concentrated among two customers.
Investor Verification Checklist
- Legal Liability: Verify the status of the Elysium Health appeal and the potential $10.4 million liability exposure.
- Revenue Sustainability: Assess the sustainability of Consumer Products growth given the significant increase in marketing spend (up 760 bps of sales).
- Ingredient Demand: Monitor the Ingredients segment for signs of recovery in pharmaceutical-grade sales and food-grade demand.
- Supply Chain: Confirm the stability of the exclusive supply agreement with W.R. Grace for NRC.
- Cash Burn: Review the trajectory of operating cash flow, which decreased significantly ($7.6M) year-over-year for the six-month period.